Brijeshkumar S Patel

Dr. Brijeshkumar S Patel

Respiratory Pediatrics and Precision Population Lab, Mayo Clinic, Rochester, Indiana, USA
orcid
Assistant Professor, Mayo Clinic, Rochester MN

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
WCWenchi Che
Wenchi Che
MMMelanie Manetsch
Melanie Manetsch
TQTimo Quante
Timo Quante
MRMostafizur Rahman
Mostafizur Rahman
BPBrijeshkumar S Patel
Brijeshkumar S Patel
AAAlaina J. Ammit
Alaina J. Ammit

22 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMelanie Manetsch
Melanie Manetsch
MRMostafizur Rahman
Mostafizur Rahman
BPBrijeshkumar S Patel
Brijeshkumar S Patel
EREmma E Ramsay
Emma E Ramsay
NRNowshin N Rumzhum
Nowshin N Rumzhum
AAAlaina J Ammit
Alaina J Ammit
Mitogen-activated protein kinase phosphatase 1 (MKP-1) represses MAPK-driven signalling and plays an important anti-inflammatory role in asthma and airway remodelling. Although MKP-1 is corticosteroid-responsive and increased by cAMP-mediated signalling, the upregulation of this critical anti-inflammatory protein by long-acting β2-agonists and clinically-used corticosteroids has been incompletely examined to date. To address this, we investigated MKP-1 gene expression and protein upregulation induced by two long-acting β2-agonists (salmeterol and formoterol), alone or in combination with the corticosteroid fluticasone propionate (abbreviated as fluticasone) in primary human airway smooth muscle (ASM) cells in vitro. β2-agonists increased MKP-1 protein in a rapid but transient manner, while fluticasone induced sustained upregulation. Together, long-acting β2-agonists increased fluticasone-induced MKP-1 and modulated ASM synthetic function (measured by interleukin 6 (IL-6) and interleukin 8 (IL-8) secretion). As IL-6 expression (like MKP-1) is cAMP/adenylate cyclase-mediated, the long-acting β2-agonist formoterol increased IL-6 mRNA expression and secretion. Nevertheless, when added in combination with fluticasone, β2-agonists significantly repressed IL-6 secretion induced by tumour necrosis factor α (TNFα). Conversely, as IL-8 is not cAMP-responsive, β2-agonists significantly inhibited TNFα-induced IL-8 in combination with fluticasone, where fluticasone alone was without repressive effect. In summary, long-acting β2-agonists increase fluticasone-induced MKP-1 in ASM cells and repress synthetic function of this immunomodulatory airway cell type.

16 November 2016 in Scientific Reports
Verified
Journal Article
Open access
MRMostafizur Rahman
Mostafizur Rahman
LPLaura Prünte
Laura Prünte
LLLeonard F. Lebender
Leonard F. Lebender
BPBrijeshkumar S Patel
Brijeshkumar S Patel
IGIngrid Gelissen
Ingrid Gelissen
AAAlaina J. Ammit
Alaina J. Ammit
Protein phosphatase 2A (PP2A) activity can be enhanced pharmacologically by PP2A-activating drugs (PADs). The sphingosine analog FTY720 is the best known PAD and we have shown that FTY720 represses production of pro-inflammatory cytokines responsible for respiratory disease pathogenesis. Whether its phosphorylated form, FTY720-P, also enhances PP2A activity independently of the sphingosine 1-phosphate (S1P) pathway was unknown. Herein, we show that FTY720-P enhances TNF-induced PP2A phosphatase activity and significantly represses TNF-induced interleukin 6 (IL-6) and IL-8 mRNA expression and protein secretion from A549 lung epithelial cells. Comparing FTY720 and FTY720-P with S1P, we show that unlike S1P, the sphingosine analogs do not induce cytokine production on their own. In fact, FTY720 and FTY720-P significantly repress S1P-induced IL-6 and IL-8 production. We then examined their impact on expression of cyclooxygenase 2 (COX-2) and resultant prostaglandin E2 (PGE2) production. S1P did not increase production of this pro-inflammatory enzyme because COX-2 mRNA gene expression is NF-κB-dependent, and unlike TNF, S1P did not activate NF-κB. However, TNF-induced COX-2 mRNA expression and PGE2 secretion is repressed by FTY720 and FTY720-P. Hence, FTY720-P enhances PP2A activity and that PADs can repress production of pro-inflammatory cytokines and enzymes in A549 lung epithelial cells in a manner devoid of S1P agonism.

1 May 2015 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
BPBrijeshkumar S Patel
Brijeshkumar S Patel
PPPavan Prabhala
Pavan Prabhala
Brian G. OliverBrian G. Oliver
Brian G. Oliver
AAAlaina J. Ammit
Alaina J. Ammit
β2-agonists are principally used in asthma to provide bronchodilation; however, they also have antiinflammatory properties, due, in part, to their ability to up-regulate mitogen-activated protein kinase phosphatase (MKP) 1 in a cAMP-dependent manner. Phosphodiesterases (PDEs) are attractive targets for potentiating the antiinflammatory response. There are 11 subfamilies of PDE enzymes; among these, inhibition of PDE3 and PDE4 are the main targets for airway smooth muscle (ASM). PDE enzymes are important intracellular regulators that catalyze the breakdown of cyclic adenosine monophosphate (cAMP) and/or 3′,5′-cyclic guanosine monophosphate to their inactive forms. Given that MKP-1 is cAMP dependent, and inhibition of PDE acts to increase β2-agonist–induced cAMP, it is possible that the presence of PDE inhibitors may enhance β2-adrenoceptor–mediated responses. We address this herein by comparing the ability of a panel of inhibitors against PDE3 (cilostamide, cilostazol, milrinone) or PDE4 (cilomilast, piclamilast, rolipram) to increase cAMP, MKP-1 mRNA expression, and protein up-regulation in ASM cells induced in response to the β2-agonist formoterol. Our data show that inhibitors of PDE4, but not PDE3, increase β2-agonist–induced cAMP and induce MKP-1 mRNA expression and protein up-regulation. When cAMP was increased, there was a concomitant increase in MKP-1 levels and significant inhibition of TNF-α–induced CXCL8 (IL-8). This result was consistent with all PDE4 inhibitors examined but not for the PDE3 inhibitors. These findings reinforce cAMP-dependent control of MKP-1 expression, and suggest that PDE4 is the predominant PDE isoform responsible for formoterol-induced cAMP breakdown in ASM cells. Our study is the first to demonstrate that PDE4 inhibitors augment antiinflammatory effects of β2-agonists via increased MKP-1 expression in ASM cells.

21 December 2015 in Allergy
Verified
Journal Article
Closed access
PDF file
NRNowshin N. Rumzhum
Nowshin N. Rumzhum
BPBrijeshkumar S Patel
Brijeshkumar S Patel
PPPavan Prabhala
Pavan Prabhala
IGIngrid C. Gelissen
Ingrid C. Gelissen
Brian G. OliverBrian G. Oliver
Brian G. Oliver
AAAlaina J. Ammit
Alaina J. Ammit

15 March 2021 in Frontiers in Physiology
Verified
Journal Article
Open access
ARAnne M. Roesler
Anne M. Roesler
JRJovanka Ravix
Jovanka Ravix
CBColleen M. Bartman
Colleen M. Bartman
BPBrijeshkumar S Patel
Brijeshkumar S Patel
MSMarta Schiliro
Marta Schiliro
YPY. S. Prakash
Y. S. Prakash
Supplemental O2 (hyperoxia), necessary for maintenance of oxygenation in premature infants, contributes to neonatal and pediatric airway diseases including asthma. Airway smooth muscle (ASM) is a key resident cell type, responding to hyperoxia with increased contractility and remodeling [proliferation, extracellular matrix (ECM) production], making the mechanisms underlying hyperoxia effects on ASM significant. Recognizing that fetal lungs experience a higher extracellular Ca2+ ([Ca2+]o) environment, we previously reported that the calcium sensing receptor (CaSR) is expressed and functional in human fetal ASM (fASM). In this study, using fASM cells from 18 to 22 week human fetal lungs, we tested the hypothesis that CaSR contributes to hyperoxia effects on developing ASM. Moderate hyperoxia (50% O2) increased fASM CaSR expression. Fluorescence [Ca2+]i imaging showed hyperoxia increased [Ca2+]i responses to histamine that was more sensitive to altered [Ca2+]o, and promoted IP3 induced intracellular Ca2+ release and store-operated Ca2+ entry: effects blunted by the calcilytic NPS2143. Hyperoxia did not significantly increase mitochondrial calcium which was regulated by CaSR irrespective of oxygen levels. Separately, fASM cell proliferation and ECM deposition (collagens but not fibronectin) showed sensitivity to [Ca2+]o that was enhanced by hyperoxia, but blunted by NPS2143. Effects of hyperoxia involved p42/44 ERK via CaSR and HIF1α. These results demonstrate functional CaSR in developing ASM that contributes to hyperoxia-induced contractility and remodeling that may be relevant to perinatal airway disease.